Eisai Co

FDA accepts Eisai’s BLA for LEQEMBI subcutaneous autoinjector for alzheimer’s disease treatment

Read more

Eisai to grant 625 mn yen to GHIT Fund for developing medicines for neglected tropical diseases, malaria

Read more

Eisai submits MAA for lecanemab in Great Britain to treat early Alzheimer’s disease

Read more

Eisai enters into agreement with Blissbio for antibody-drug conjugate BB-1701

Read more

Biogen scraps two late-stage trials for Alzheimer’s treatment

Read more

DRL in agreement with Eisai Co, Japan

Read more